LS-C18920

antibody from LSBio

Targeting: GSK3A

ELISA

Immunocytochemistry

Antibody data

Submit

Validation data

Product number: LS-C18920 - Provider product page
Provider: LSBio
Product name: GSK3A / GSK3 Alpha Antibody (phospho-Ser21) LS-C18920
Antibody type: Polyclonal
Description: Affinity purified
Reactivity: Human
Host: Rabbit
Isotype: IgG
Storage: Store vial at -20°C prior to opening. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20°C or below. Avoid freeze-thaw cycles.

GSK3A protein structure - LS-C18920 shown in red.

Supportive validation

Submitted by: LSBio (provider)
Enhanced method: Genetic validation
Main image
Experimental details: Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.

Enhanced validation

Submitted by: LSBio (provider)
Enhanced method: Genetic validation
Main image
Experimental details: Anti-GSK3A Antibody - Western Blot. Western blot of Affinity Purified anti-GSK3A antibody shows detection of a 52 kD band corresponding to human GSK3A in various human derived 293T cell extracts. Cells were serum starved for 24 h. Lane 1: control, Lane 2: treated with IGF-1 (100 ng/ml) for 20 min, Lane 3: pre-treated with 10 uM LY294002 (selective PI3K inhibitor) and treated with IGF-1 (100 ng/ml) for 20 min. Lane 1 shows some baseline GSK3A reactivity that is intensified upon stimulation (lane2) and diminished when an inhibitor is added (lane 3). Approximately 20 ug of lysate was run on a SDS-PAGE and transferred onto nitrocellulose followed by reaction with a 1:1000 dilution of anti-GSK3A antibody. Signal was detected using standard techniques. Personal communication, Angela Carter, Experimental Therapeutics, Ontario Cancer Inst, Toronto, Canada.